Can primary care teams tackle opioid addiction and depression together?

NCT ID NCT04245423

Completed Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a collaborative care model for people with opioid use disorder and depression, anxiety, or PTSD. 567 adults received medication (buprenorphine-naloxone or naltrexone) along with therapy and support from a primary care team. The goal was to reduce opioid use and improve mental health symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: buprenorphine-naloxone and extended-release injectable naltrexone
What this could lead to: If successful, this model could improve treatment access and outcomes for people with opioid use disorder and co-occurring mental health conditions in primary care settings.
What could go wrong: This is a completed study, but results may not apply to all populations or settings. The model relies on specific medications and therapies that may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder Depression depressive disorder opiate dependence post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENTAL HEALTH CONDITIONS OPIOID-USE DISORDER

Contacts and locations

Locations

Penn Center for Primary Care

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.